Twist Bioscience (NASDAQ:TWST) Given New $45.00 Price Target at Barclays

Twist Bioscience (NASDAQ:TWST) had its price objective boosted by Barclays from $40.00 to $45.00 in a research note published on Friday morning, Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts have also recently commented on TWST. The Goldman Sachs Group upgraded Twist Bioscience from a neutral rating to a buy rating and raised their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Robert W. Baird raised their price target on Twist Bioscience from $39.00 to $40.00 and gave the company an outperform rating in a report on Friday. Finally, Scotiabank upped their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a sector outperform rating in a report on Monday, February 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of Buy and an average price target of $42.50.

Twist Bioscience Stock Performance

TWST stock opened at $44.67 on Friday. The stock’s fifty day moving average is $34.11 and its two-hundred day moving average is $31.34. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -13.29 and a beta of 1.64. Twist Bioscience has a 1 year low of $11.81 and a 1 year high of $44.90.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same period in the previous year, the business posted ($1.06) EPS. Twist Bioscience’s revenue was up 25.1% on a year-over-year basis. As a group, analysts predict that Twist Bioscience will post -3.17 EPS for the current fiscal year.

Insider Activity

In related news, CEO Emily M. Leproust sold 1,128 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the transaction, the chief executive officer now owns 515,281 shares of the company’s stock, valued at $17,272,219.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Emily M. Leproust sold 1,128 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the sale, the chief executive officer now directly owns 515,281 shares in the company, valued at approximately $17,272,219.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,132 shares of the firm’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total transaction of $37,061.68. Following the sale, the chief executive officer now owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The disclosure for this sale can be found here. Insiders sold a total of 13,211 shares of company stock worth $449,573 over the last 90 days. 3.92% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of TWST. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Twist Bioscience by 23.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,617 shares of the company’s stock worth $316,000 after buying an additional 2,933 shares during the period. Strs Ohio lifted its position in shares of Twist Bioscience by 6.5% in the 3rd quarter. Strs Ohio now owns 27,900 shares of the company’s stock valued at $565,000 after acquiring an additional 1,700 shares in the last quarter. Rockland Trust Co. boosted its stake in Twist Bioscience by 29.7% in the 3rd quarter. Rockland Trust Co. now owns 38,500 shares of the company’s stock worth $780,000 after purchasing an additional 8,808 shares during the period. TD Asset Management Inc grew its position in Twist Bioscience by 137.7% during the 3rd quarter. TD Asset Management Inc now owns 73,148 shares of the company’s stock worth $1,482,000 after purchasing an additional 42,374 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Twist Bioscience by 51.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after purchasing an additional 1,179 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.